Cited by 772Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

Open access
Cannon, Christopher P., Steinberg, Benjamin A., Murphy, Sabina A., Mega, Jessica L., Braunwald, Eugene·2006·Journal of the American College of Cardiology

Abstract

Objectives The purpose of this study was to conduct a meta-analysis that compares the reduction of cardiovascular outcomes with high-dose statin therapy versus standard dosing.Background Debate exists regarding the merit of more intensive lipid lowering with high-dose statin therapy as compared with standard-dose therapy.Methods We searched PubMed and article references for randomized controlled trials of intensive versus standard-dose statin therapy enrolling more than 1,000 patients with either stable coronary heart disease or acute coronary syndromes. Four trials were identified: the TNT (Treating to New Targets) and the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid-Lowering) trials involved patients with stable cardiovascular disease, and the PROVE IT-TIMI-22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction-22) and A-to-Z (Aggrastat-to-Zocor) trials involved patients with acute coronary syndromes. We carried out a meta-analysis of the relative odds on the basis of a fixed-effects model using the Mantel-Haenszel method for the major outcomes of death and cardiovascular events.Results A total of 27,548 patients were enrolled in the 4 large trials. The combined analysis yielded a significant 16% odds reduction in coronary death or myocardial infarction (p < 0.00001), as well as a significant 16% odds reduction of coronary death or any cardiovascular event (p < 0.00001). No difference was observed in total or non-cardiovascular mortality, but a trend toward decreased cardiovascular mortality (odds reduction 12%, p = 0.054) was observed.Conclusions Intensive lipid lowering with high-dose statin therapy provides a significant benefit over standard-dose therapy for preventing predominantly non-fatal cardiovascular events.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2006.04.070

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Such small changes in LDL-C levels do not seem to affect cardiovascular outcomes with statin administration.

    “Such small changes in LDL-C levels do not seem to affect cardiovascular outcomes and serum lipid profiles with statin administration, which can reduce the LDL-C level by approximately 50 mg/dL (40).”

    From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [40]

    The Results report that a 26 mg/dL difference in LDL-C between statin treatment groups accompanied a significant 16% reduction in coronary death or myocardial infarction. The Discussion likewise says that this LDL-C difference would be expected to reduce cardiovascular events by about 14%, and that the observed reduction was 16%. This is contrary to the claim that such changes do not seem to affect cardiovascular outcomes. (LLM, conf=0.91)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Such small changes in LDL-C levels do not seem to affect serum lipid profiles with statin administration.

    “Such small changes in LDL-C levels do not seem to affect cardiovascular outcomes and serum lipid profiles with statin administration, which can reduce the LDL-C level by approximately 50 mg/dL (40).”

    From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [40]

    The Results report LDL-C levels under standard- and high-dose statin therapy, but do not assess whether small LDL-C changes leave serum lipid profiles unaffected. The Discussion addresses LDL-C reduction and cardiovascular events, not the claimed lack of effect on serum lipid profiles. Searches for that claim and for serum lipid profiles found no supporting passage. (LLM, conf=0.72)

    Experimental — accuracy not yet measured
  • Diabetes confers excess mortality risk following acute coronary syndrome despite modern therapies.

    “Importantly, DM confers excess mortality risk following ACS despite modern therapies”
  • No increases in new-incidence cancer or non-CVD deaths were observed with long-term LDL-C-lowering therapy using statins.

    “No increases in new-incidence cancer or non-CVD deaths were observed, which reconfirms the safety of long-term LDL-C-lowering therapy using statins.”
  • Early initiation of LDL-C-lowering therapy regardless of the plasma LDL-C level was useful for the long-term prevention of cardiovascular events and all-cause mortality in high-risk patients.

    “The long-term follow-up of large clinical trials of statins that were conducted in the 1990s, such as the West of Scotland Coronary Prevention Study (WOSCOPS) and the Heart Protection Study (HPS)628, 629) confirmed that early initiation of LDLC-lowering therapy regardless of the plasma LDL-C level was useful for the long-term prevention of cardiovascular events and all-cause mortality in high-risk”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Pedersen TR, Faergeman O, Kastelein JJ, et al., Incremental Decrease in End Points Through Aggressive Lipid-Lowering Study Group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a random- ized controlled trial. JAMA 2005;294:2437-45.

Cited by

Sorted by citations

Authors
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Cannon, Christopher P.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2006-08
Volume
48
Issue
3
Pages
438-445
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2040462758
Cited by
770
References
27
Citations by year
2026: 6 · 2025: 13 · 2024: 20 · 2023: 24 · 2022: 22 · 2021: 23 · 2020: 36 · 2019: 26 · 2018: 30 · 2017: 36 · 2016: 35 · 2015: 28 · 2014: 43 · 2013: 46 · 2012: 48
FWCI
12.90
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
high-intensity statin therapy, intensive lipid lowering, statin therapy, cardiovascular outcomes, coronary artery disease, acute coronary syndrome, myocardial infarction, coronary death, cardiovascular mortality, TNT trial, IDEAL trial, PROVE IT-TIMI 22, pravastatin, atorvastatin
MeSH terms
Cardiovascular Diseases, Coronary Disease, Dose-Response Relationship, Drug, Humans, Syndrome, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review